Steba Biotech's TOOKAD(R) Vascular Photodynamic Therapy Maintains Significant Reduction in Overall Progression and Conversion to Radical Therapy in Low-risk Prostate Cancer Patients at 4 Years

LUXEMBOURG, June 20, 2018 -- (Healthcare Sales & Marketing Network) -- Steba Biotech, a privately-owned biotechnology company focused on the development of innovative and minimally invasive photodynamic therapies and systems to treat cancers, today announ... Biopharmaceuticals, Urology, Oncology Steba Biotech, photodynamic therapy, TOOKAD, prostate cancer
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news